While prior meta-analyses (27–30) had shown the effectiveness and safety of PD-1 inhibitors combined with chemotherapy as first-line treatment for advanced HER2-negative GC, they failed to include the updated information on the long-term outcomes of RCTs. This evidence concerns the gene PDCD1 and gastric cancer.